ASCO-GI 2021: Pembrolizumab Bests Chemotherapy as First-Line Option in Select Metastatic Colorectal Cancer Patients
Results highlight the need to incorporate biomarkers into clinical trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.